The American Society of Clinical Oncology 2013 Annual Meeting took place from May 31 until June 4 2013 in Chicago (IL, USA). Highlights within the area of gynecological oncology and breast cancer included two studies in cervical cancer addressing screening as well as treatment of advanced disease. In breast cancer, the presented studies covered a wide range of topics from local therapy to targeted therapy in the advanced setting. They were not practice changing but rather for the most part confirmatory of earlier findings. Last but not least, a positive Phase III study, BOLERO III, proved the hypothesis that trastuzumab resistance can be overcome by intracellular signal transduction using the mTOR inhibitor everolimus.